HYALGAN® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics, eg, acetaminophen.¹⁰

Contraindication:

HYALGAN® is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site.¹⁰

Proven

6 months of pain relief in the largest controlled pivotal study of any hyaluronate⁸
Demonstrated efficacy with 3 injections^*11-14

*Some patients may experience benefit with 3 injections given at weekly intervals; this benefit has been noted in studies reported in the literature in which patients treated with 3 injections were followed for 60 days.¹⁰

Recommended earlier

Greater clinical benefit when used earlier in the disease process²⁴
Recommended before, during, and after COX-2 and NSAID treatment¹⁶^,²¹

Recommended before, during, and after COX-2 and NSAID treatment¹⁶^,²¹

Adapted from ACR guidelines and recommendations of the Hyaluronan Consensus Group^† of orthopaedic surgeons.

^†Sponsored by sanofi-aventis U.S.

Repeatable

The only hyaluronan proven safe for repeat use in a 30-month study
Incremental improvement in pain relief with repeat cycles²⁵

Reliable

Nonsystemic treatment option targets the knee, not the whole body²¹
No known drug-drug interactions²⁶
No published reports of psedoseptic reactions in clinical trials

Defining a pseudoseptic reaction

HYALGAN® is covered by Medicare and most managed care plans^§

^§ Data on file, sanofi-aventis U.S. LLC.

Important Safety Information for HYALGAN®

HYALGAN® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpha-rmacologic therapy, and to simple analgesics, eg, acetaminophen
HYALGAN® is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site
The effectiveness of a single treatment cycle of less than 3 injections has not been established
In the US clinical trial of 495 patients, the only adverse event showing statistical significance vs placebo was injection-site pain
Other adverse events included gastrointestinal complaints, headache, local ecchymosis and rash, local joint pain and swelling, and local pruritus. However, the incidence of these events was similar in the HYALGAN®-treated and placebo groups
In other clinical studies, the frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a single treatment cycle

Click here for additional important information for HYALGAN®.

Facts About HYALGAN®

HYALGAN® is the first FDA-approved hyaluronate therapy

to treat OA knee pain in the US

Recommended before, during, and after COX-2 and NSAID treatment16,21

Defining a pseudoseptic reaction

HYALGAN® is covered by Medicare and most managed care plans§

Recommended before, during, and after COX-2 and NSAID treatment¹⁶^,²¹

HYALGAN® is covered by Medicare and most managed care plans^§